GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Bioqual Inc (OTCPK:BIOQ) » Definitions » Cash Flow from Financing

Bioqual (Bioqual) Cash Flow from Financing : $-0.85 Mil (TTM As of May. 2018)


View and export this data going back to . Start your Free Trial

What is Bioqual Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in May. 2018, Bioqual paid $0.00 Mil more to buy back shares than it received from issuing new shares. It spent $0.32 Mil paying down its debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent $0.54 Mil paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Bioqual spent $0.85 Mil on financial activities for the six months ended in May. 2018.


Bioqual Cash Flow from Financing Historical Data

The historical data trend for Bioqual's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioqual Cash Flow from Financing Chart

Bioqual Annual Data
Trend May01 May03 May04 May05 May06 May07 May10 May11 May17 May18
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.08 -0.18 -0.19 -0.71 -0.85

Bioqual Semi-Annual Data
May96 May97 May98 May99 May00 May01 May03 May04 May05 May06 May07 May10 May11 May17 May18
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -0.18 -0.19 -0.71 -0.85

Bioqual Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Bioqual's Cash from Financing for the fiscal year that ended in May. 2018 is calculated as:

Bioqual's Cash from Financing for the quarter that ended in May. 2018 is:


For stock reported annually, GuruFocus uses latest annual data as the TTM data. Cash Flow from Financing for the trailing twelve months (TTM) ended in May. 2018 was $-0.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioqual  (OTCPK:BIOQ) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Bioqual's issuance of stock for the six months ended in May. 2018 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Bioqual's repurchase of stock for the six months ended in May. 2018 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Bioqual's net issuance of debt for the six months ended in May. 2018 was $-0.32 Mil. Bioqual spent $0.32 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Bioqual's net issuance of preferred for the six months ended in May. 2018 was $0.00 Mil. Bioqual paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Bioqual's cash flow for dividends for the six months ended in May. 2018 was $-0.54 Mil. Bioqual spent $0.54 Mil paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Bioqual's other financing for the six months ended in May. 2018 was $0.00 Mil. Bioqual received $0.00 Mil on other financial activities.


Bioqual Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Bioqual's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioqual (Bioqual) Business Description

Traded in Other Exchanges
N/A
Address
9600 Medical Center Drive, Suite 101, Rockville, MD, USA, 20850
Bioqual Inc is a United States-based medical research company. It is engaged in providing contract research services focused on animal models of human diseases, including AIDS, influenza, RSV infection, flavivirus infections like Zika and Dengue, malaria, hepatitis, and cancer. The company is also involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. It provides services to the federal government, universities, and the life science and pharmaceutical industries. It derives revenue from the provision of contract research services.
Executives
Williams Frank E Jr other: Communication, See Remarks 2789-B HARTLAND ROAD, FALLS CHURCH VA 22043

Bioqual (Bioqual) Headlines

No Headlines